Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial

Fawzy M, Muhammad Fawzy, Mesbah Y, Yasser Mesbah
Archives of gynecology and obstetrics · 2015 · vol. 292(6) , pp. 1267–1271 · doi:10.1007/s00404-015-3755-5 · PMID:25990480 · W291097451
article OA: closed CC0 ⤵ 47 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-27 ⓘ

This trial compared oral dienogest and triptorelin acetate for adenomyosis symptoms, finding both reduced pelvic pain but triptorelin acetate was more effective for menorrhagia and uterine volume reduction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text ⓘ

This prospective clinical trial compared oral dienogest (2 mg/day) versus depot triptorelin acetate (3.75 mg every 4 weeks) over 16 weeks in 41 premenopausal women with uterine adenomyosis experiencing pelvic pain and menorrhagia, with outcomes calculated at baseline and after 16 weeks. Both treatments produced significant reductions in pelvic pain, and dienogest was reported as equivalent to triptorelin acetate for pelvic pain relief, while triptorelin acetate was more effective in controlling menorrhagia and reducing uterine volume. Nineteen of 22 (86.4%) in the dienogest group and 18 of 19 (94.7%) in the triptorelin group completed the trial. The paper is centrally about adenomyosis—comparing dienogest versus triptorelin acetate for pelvic pain and menorrhagia in women with uterine adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PurposeTo compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis.MethodsA total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks but mean values were calculated at baseline and after 16 weeks (end of treatment).ResultsA total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial. Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate. Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.ConclusionsDienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis.
Full text 7,974 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Purpose To compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis.

Methods

A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks but mean values were calculated at baseline and after 16 weeks (end of treatment).

Results

A total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial. Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate. Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.

Conclusions

Dienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis. Similar content being viewed by others

References

Wang PH, Su WH, Sheu BC, Liu WM (2009) Adenomyosis and its variance: adenomyoma and female fertility. Taiwan J Obstet Gynecol 48:232–238 Kitawaki J (2006) Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 20:493–502 Wood C (2001) Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc 7:89–95 Kitamura Y, Allison SJ, Jha RC, Spies JB, Flick PA, Ascher SM (2006) MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 186:855–864 Sheng J, Zhang WY, Zhang JP, Lu D (2009) The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 79:18993 Nelson JR, Corson SL (1993) Long-term management of adeno-myosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril 59:441–443 Ahmed B, Aboubakr E, Alaa M (2012) Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 91:489–495 Oettel M, Breitbarth H, Elger W et al (1999) The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 4:2–13 Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108(1):21–25 Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Sørensen JS, Olesen F (2001) Magnetic resonance imaging and transvaginal ultrasonography for diagnosis of adenomyosis. Fertil Steril 76:588–594 Nishida M, Takano K, Arai Y, Ozone H, Ichikawa R (2010) Conservative surgical management for diffuse uterine adenomyosis. Fertil Steril 94(2):715–719 Grimbizis GF, Mikos T, Tarlatzis B2 (2014) Uterus-sparing operative treatment for adenomyosis. Fertil Steril 101(2):472–487 Strowitzki T, Marr J, Gerlinger C et al (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633–641 Harada M, Osuga Y, Izumi G, Takamura M, Takemura Y, Hirata T, Yoshino O, Koga K, Yano T, Taketani Y (2011) Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study. Gynecol Endocrinol 27(9):717–720 Hirata Tetsuya, Izumi Gentaro, Takamura Masashi, Saito Ako, Nakazawa Akari, Harada Miyuki, Hirota Yasushi, Koga Kaori, Fujii Tomoyuki, Osuga Yutaka (2014) Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol 30(10):726–729 Foster RH, Wilde MI (1998) Dienogest. Drugs 56:825–833 Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N (2005) Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8productionvi a nuclear factor kappaB inactivation in endometriotic stromalcells. Fertil Steril 83:1530–1535 Yamanaka A, Kimura F, Kishi Y, Takahashi K, Suginami H, Shimizu Y, Murakami T (2014) Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur J Obstet Gynecol Reprod Biol 179:170–174 Kang JL, Wang XX, Nie ML, Huang XH (2009) Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest 69:73–77 Morelli Michele, Rocca Morena Luigia, Venturella Roberta, Mocciaro Rita, Zull Fulvio (2013) Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol 29(4):305–308 Hudelist G, Oberwinkler KH, Singer CF et al (2009) Combination of transvaginal sonography and clinical examination for preoperative diagnosis of pelvic endometriosis. Hum Reprod 24:1018–1024 Fedele L, Bianchi S, Dorta M, Arcaini L, Zanotti F, Carinelli S (1992) Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril 58:94–97 Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, Masuzaki H (2010) Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod 25(11):2878–2890 Grow DR, Filer RB (1991) Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol 78:538–539 Graser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oette LM (2000) Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest—a dose-ranging study. Maturitas 35:253–261 Irahara M, Harada T Momoeda M, Tamaki Y (2007) Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 6:223–228 Nagata C, Yanagida S, Okamoto A et al (2012) Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 38:639–644 Napolitano M, Dolce A, Celenza G, Grandone E, Perilli MG, Siragusa S, Carta G, Orecchioni A, Marian G (2014) Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. Ann Hematol 93:557–563 Warner PE, Critchley HO, Lumsden MA et al (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229 Parsanezhad M, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt E (2010) A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 93:192–198 Bazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine JM et al (2001) Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 16:2427–2433 Conflict of interest No potential conflict of interest relevant to this article was reported. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Fawzy, M., Mesbah, Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet 292, 1267–1271 (2015). https://doi.org/10.1007/s00404-015-3755-5 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00404-015-3755-5

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosischronic_pelvic_painadenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Endometriosis Endometriosis Nandrolone Nandrolone Nandrolone Nandrolone Premenopause Triptorelin Pamoate Triptorelin Pamoate Triptorelin Pamoate Administration, Oral Adult Female Humans Injections, Subcutaneous Menorrhagia Menorrhagia Menorrhagia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (49)

Source provenance

europepmc
last seen: 2026-08-02T06:10:09.037253+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:52.213533+00:00
License: CC0 · commercial use OK